Lundbeck advances Parkinson's research with new Phase 1b data at AD/PD™ 2026

Contributed by: PR Newswire

Tags

H-Lundbeck-A/S

More Like This

Lundbeck to showcase amlenetug Phase 3 MASCOT trial design in Multiple System Atrophy at the International Congress of Parkinson's Disease and Movement Disorders® 2025

Prothena Partners Present Data Supporting Next Generation Treatments for Parkinson’s and Alzheimer’s Disease at AD/PD™ 2026

Lundbeck to share pipeline data and key insights into the progression of rare disease, Multiple System Atrophy, at International MSA Congress in Boston

Latest data on long-term, real-world treatment with lecanemab will be presented at the AD/PD™ 2026 congress

Prothena’s Partner Roche to Advance Prasinezumab into Phase III Development for Early-Stage Parkinson's Disease

New data on long-term, real-world treatment with lecanemab presented at the 2026 AD/PD™ congress

Lundbeck to showcase new neurology data at the American Academy of Neurology Annual Meeting

Roche’s Phase IIb Study of Prasinezumab Missed Primary Endpoint, But Suggests Possible Clinical Benefit in Early-Stage Parkinson’s Disease